Galectin-1–driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance

Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming

(2017) Lin Tian et al.   NATURE

Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes

(2017) Xinqi Wu et al.   Cancer Immunology Research

Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy

(2017) Andrea Facciabene et al.   OncoImmunology

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

(2016) Joseph L. Benci et al.   CELL

Glycosylation-Dependent IFN-γR Partitioning in Lipid and Actin Nanodomains Is Critical for JAK Activation

(2016) Cédric M. Blouin et al.   CELL

Shaping the Immune Landscape in Cancer by Galectin-Driven Regulatory Pathways

(2016) Gabriel A. Rabinovich et al.   JOURNAL OF MOLECULAR BIOLOGY

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

(2016) P.-L. Chen et al.   Cancer Discovery

Metastatic model of HPV+ oropharyngeal squamous cell carcinoma demonstrates heterogeneity in tumor metastasis

(2016) Daniel W. Vermeer et al.   Oncotarget

Immune response modulation by Galectin-1 in a transgenic model of neuroblastoma

(2016) Gabriele Büchel et al.   OncoImmunology

Targeting the tumor vasculature to enhance T cell activity

(2015) Evripidis Lanitis et al.   CURRENT OPINION IN IMMUNOLOGY

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

Robust enumeration of cell subsets from tissue expression profiles

(2015) Aaron M Newman et al.   NATURE METHODS

STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity

(2015) Olivier Demaria et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

T cell exclusion, immune privilege, and the tumor microenvironment

(2015) J. A. Joyce et al.   SCIENCE

Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade

(2014) S. J. Dovedi et al.   CANCER RESEARCH

Galectin-1 Pulls the Strings on VEGFR2

(2014) Pamela Stanley   CELL

Glycosylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory Tumors

(2014) Diego O. Croci et al.   CELL

Galectin-1 Mediates Radiation-Related Lymphopenia and Attenuates NSCLC Radiation Response

(2014) P. Kuo et al.   CLINICAL CANCER RESEARCH

Galectin-1 and -9 in angiogenesis: A sweet couple

(2014) V. L. Thijssen et al.   GLYCOBIOLOGY

Differential Roles of Galectin-1 and Galectin-3 in Regulating Leukocyte Viability and Cytokine Secretion

(2014) S. R. Stowell et al.   JOURNAL OF IMMUNOLOGY

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

(2014) Gregory T Motz et al.   NATURE MEDICINE

Control of the Adaptive Immune Response by Tumor Vasculature

(2014) Laetitia Mauge et al.   Frontiers in Oncology

Comparative Analysis of Tumor-Infiltrating Lymphocytes in a Syngeneic Mouse Model of Oral Cancer

(2012) Nancy P. Judd et al.   OTOLARYNGOLOGY-HEAD AND NECK SURGERY

Galectin-1 research in T cell immunity: Past, present and future

(2011) Filiberto Cedeno-Laurent et al.   CLINICAL IMMUNOLOGY

Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis

(2011) Wei-Ting Hwang et al.   GYNECOLOGIC ONCOLOGY

Tumor angiogenesis: molecular pathways and therapeutic targets

(2011) Sara M Weis et al.   NATURE MEDICINE

Mechanism of tumor cell-induced T-cell apoptosis mediated by galectin-1

(2009) Ferenc Kovács-Sólyom et al.   IMMUNOLOGY LETTERS

The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy

(2007) Sven Saussez et al.   ORAL ONCOLOGY